Patent applications published 30 March 2011
Selected patent applications from the weekly European Patents Bulletin
- Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
Ben Gurion University of the Negev R&D Authority 2299809*
- Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Dow Pharmaceutical Services 2299810*
- Targeting TGF as a therapy for Alzheimer’s disease
Yale University 2299812*
- Branched 3- and 6-substituted quinolines as CGRP receptor antagonists
Merck Sharp & Dohme 2299813*
- Compsns, syntheses, and methods of using piperazine-based antipsychotic agents
Reviva Pharmaceuticals 2299814*
- Method of treating burns using avermectin compound
Galderma 2299815*
- Inhibitors of janus kinases
Merck Sharp & Dohme 2299816*
- Pyridine classical cannabinoid compounds and related methods of use
The University of Tennessee Research Foundation 2299817*
- Pyrimidine classical cannabinoid compounds and related methods of use
The University of Tennessee Research Foundation 2299818*
- Pyridine non-classical cannabinoid and related methods of use
The University of Tennessee Research Foundation 2299819*
- Ophthalmic formulation of rho kinase inhibitor compound
Inspire Pharmaceuticals 2299820*
- Novel tricyclic compounds
Abbott Laboratories 2299821*
- Method for treating neurodegenerative dysfunction
Tonic Pharmaceuticals 2299822*
- Pyrimidine non-classical cannabinoid compounds and related methods of use
The University of Tennessee Research Foundation 2299823*
- Pyrazole derivatives useful as inhibitors of FAAH
Merck Sharp & Dohme 2299824*
- Inhibitors of AKT activity
Merck Sharp & Dohme; Banyu Pharmaceutical 2299825*
- Compsns and methods for attenuating the formation of A2E in the retinal pigment epithelium
University of Utah 2299826*
- Solid pharmaceutical formulations comprising BIBW 2992
Boehringer Ingelheim International 2299971*
- Topical compsns
Ornegatri 2299972*
- Pharmaceutical preparation comprising permethylated cyclodextrin
Roewer, Norbert; Broscheit, Jens 2299973*
- Pharmaceutical compsns containing a fluoroquinolone antibiotic drug
Alcon 2299974*
- Preparation and iontophoretic device for the transdermal application of active ingredients
LTS Lohmann Therapie-Systeme 2299975*
- Controlled release auris sensory cell modulator compsns and methods for the treatment of otic disorders
Otonomy; The Regents of the University of California 2299976*
- Liposomes for drug delivery and methods for preparation thereof
Liplasome Pharma 2299977*
- Single dosage pharmaceutical formulation comprising eprosartan mesylate
LEK Pharmaceuticals 2299978*
- Controlled release antimicrobial compsns and methods for the treatment of otic disorders
Otonomy; The Regents of the University of California 2299979*
- Silicon dioxide nanoparticles and their use for vaccination
Merck Patent 2299980*
- Sublingual compsns comprising (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine
AstraZeneca 2299981*
- Directly injection mouldable and rapidly disintegrating tablet matrix
Merck Patent 2299982*
- Stabilised atypical antipsychotic formulation
Handa Pharmaceuticals 2299983*
- Oral formulations of cytidine analogues and methods of use thereof
Celgene Corp 2299984*
- Diagnostic reagent, containing bioparticles, method for production thereof and use thereof as internal standard in nucleic acid preparation and nucleic acid detection methods
Qiagen 2299985*
- A chronotherapeutic pharmaceutical dosage form
University of the Witwatersrand 2299986*
- Capsule pharmaceutical dosage form comprising a suspension formulation of an indoline derivative
Boehringer Ingelheim International 2299987*
- Silk polymer-based adenosine release: therapeutic potential for epilepsy
Trustees of Tufts College 2299988*
- Stabilised transdermal drug delivery system
Mylan Laboratories 2299989*
- Novel embedment particles for inhalation
Boehringer Ingelheim International 2299990*
- A method for increasing bone density and/or reducing any osteochondral defects in an animal and a compsn including vitamin K
Biffin, John Ray; Regtop, Hubeertus Leonardus 2299991*
- Process for preparing and drying solid rasagiline base
Teva Pharmaceutical Industries 2299992*
- Process for purifying rasagiline base
Teva Pharmaceutical Industries 2299993*
- L-carnitine and alkanoyl L-varnitine phytakes and process for preparing same
Scian Laboratories 2299994*
- Combination of amidine derivatives with cyclic depsipeptides
Bayer Animal Health 2299995*
- 5-lipoxygenase inhibitors
Jackson, William Paul 2299996*
- Use of nitrated lipids for treatment of side effects of toxic medical therapies
University of Utah Research Foundation 2299997*
- Medium-chain length fatty acids and glycerides as nephroprotection agents
ProMetic BioSciences 2299998*
- Stat3 inhibitors
Baylor College of Medicine 2299999*
- Methods and compsns for reducing inflam-mation and treating inflammatory disorders
University of Massachusetts 2300000*
- Dronedarone for the prevention of permanent atrial fibrillation
Sanofi-Aventis 2300001*
- Escalating dosing regimen for effecting weight loss and treating obesity
Vivus 2300002*
- Methods of treating injury associated with exposure to an alkylating species
National Jewish Health 2300003*
- Compsns and methods relating to heat shock transcription factor activating compounds and targets thereof
Duke University 2300004*
- Small molecule inhibitors of Botulinum neurotoxins
The United States of America, as represented by the Secretary of the Army 2300005*
- N-piperidinyl acetamide derivatives as calcium channel blockers
Zalicus Pharmaceutical 2300007*
- Supplementation of propane-1,2,3-triol and water in fasting subjects
Lück, Stephan 2300008*
- Oral administration of peripherally-acting opioid antagonists
Nektar Therapeutics 2300009*
- Organic compounds
Novartis 2300010*
- Therapeutic methods and compounds
DMI Life Sciences 2300011*
- Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity
University of South Florida 2300012*
- Phosphorous derivatives as kinase inhibitors
ARIAD Pharmaceuticals 2300013*
- Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
Novartis 2300014*
- Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
Emory University 2300015*
- 6-substituted estradiol derivatives and methods of use
Endece 2300016*
- MIRNAs as therapeutic targets in cancer
The Research Foundation of State University of New York 2300017*
- Paeoniflorin preparations and use thereof for fat reduction
Profound Asia Technology 2300018*
- Antisense formulation
Oncogenex Technologies 2300019*
- Nutritive compsns and methods of using same
Pentec Health 2300020*
- A conjugate of a polymer, an antiangiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions
Ramot at Tel-Aviv University; The University of Utah Research Foundation 2300021*
- Regulatory B cells and their uses
Duke University 2300022*
- Microorganisms for preventing and treating neoplasms accompanying cellular therapy
Genelux 2300023*
- Method for decreasing borborygmi by administering a Bifidobacterium bacteria
Compagnie Gervais Danone 2300024*
- Treatment of gut motility disorders
NV Nutricia 2300025*
- Compsns obtained from Chlorella extract having immunomodulating properties
Ocean Nutrition Canada 2300026*
- Method of treating migraine using guava
Amerilab Technologies 2300027*
- Pharmaceutical compsn comprising extracts of Huanglian and Ku ding cha effective for lowering blood lipid levels
Afexa Life Science 2300028*
- Rice bran extracts for inflammation and methods of use thereof
Rice Science 2300029*
- Methods and compsns for oral administration of exenatide
Oramed 2300031*
- Metal abstraction peptide (MAP) tag and associated methods
University of Kansas 2300032*
- Collagen peptide conjugates and uses therefor
Purdue Research Foundation 2300033*
- XBP1, CD138, and CS1 peptides
Dana-Farber Cancer Institute 2300034*
- GIP-based mixed agonists for treatment of metabolic disorders and obesity
Indiana University Research and Technology 2300035*
- Melanocortin receptor-specific peptides for treatment of sexual dysfunction
Palatin Technologies 2300036*
- Glucagon/GLP-1 receptor co-agonists
Indiana University Research and Technology 2300037*
- Improved modulators of cholesterol efflux
The Regents of the University of California 2300038*
- Anxiolytic compsn containing alpha S1 casein-derived peptides
Institut National Polytechnique de Lorraine; Universite de Nancy 1 Henri Poincare 2300039*
- Methods and compsns for prostate cancer immunotherapy
Beth Israel Deaconess Medical Centre 2300040*
- Compsns and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
The Johns Hopkins University 2300041*
- Compsns and methods to treat urinary incontinence
The Cleveland Clinic Foundation 300042*
- Analgesic effects of peptide toxin APETX2
Centre National de la Recherche Scientifique - CNRS; Université Nice Sophia Antipolis 2300043*
- Methods and compsns for the management of pain using omega-conotoxins
Relevare Aust. Pty 2300044*
- Treatment of metastatic tumours
Transmolecular 2300045*
- Super fast-acting insulin compsns
Halozyme 2300046*
- Heat-stable, aqueous lactoferrin compsn and its preparation and use
Campina Nederland Holding 2300047*
- Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
Versitech; R&C Biogenius 2300048*
- Use of a dead box RNA helicase for inducing cytokine production
Institut Pasteur; Institut Pasteur de Tunis 2300049*
- Vaccine for the treatment of Alzheimer’s disease
Merck Sharp & Dohme 2300050*